Evidence Table N2. CONTINUOUS outcomes for class OTHER.

Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

N.01.02 Gugulipid Tetracycline

325 Inflammatory change (%) Mid (12) Percent change: -68 Percent change: -65

Parallel Sev

È N=20 NS

Non-inflammatory change (%) Mid (12) Percent change: -12 Percent change: -11 NS

N.01.03 Isolutrol Benzoyl peroxide

94 Inflammatory (count)

Count location: Face. Baseline counts: 24 

(Target) / 33 (Comparator)

Short (4) Percent Change*: -16 Percent Change*: -34

Parallel Mild/mod

N=70

Non-inflammatory (count)

Count location: Face. 

Short (4) Raw count: 20 Raw count: 17

Inflammatory (count)

Count location: Face. Baseline counts: 24 

(Target) / 33 (Comparator)

Mid (12) Percent Change*: -33 .06 Percent Change*: -67 .003

Non-inflammatory (count) Mid (12) Raw count: 17 .0002 Raw count: 12 .0001

N.01.05 Tea tree oil Benzoyl peroxide

18 Inflammatory (count)

Count location: 3 + c face. Baseline counts: 35 

(Target) / 38 (Comparator)

Short (4) Percent Change*: -38 Percent Change*: -50

Parallel Mod

È N=124 0.05

Non-inflammatory (count)

Count location: 3 + c face. 

Short (4) Raw count: 32 Raw count: 25 NS

Inflammatory (count)

Count location: 3 + c face. Baseline counts: 35 

(Target) / 38 (Comparator)

Mid (12) Percent Change*: -68 .001 Percent Change*: -47 .001 0.001

Non-inflammatory (count)

Count location: 3 + c face. 

Mid (12) Raw count: 15 .05 Raw count: 16 .01 NS

N.02.01 Clobetasol Vehicle

175 Inflammatory (count)

Baseline counts: 31 (Target) / 33 

(Comparator)

Short (3) Percent Change*: 00 Percent Change*: 00

Parallel split face 

Mod

È N=11 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 1 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

Hydrocortisone + buttoxethyl 

nicotinate + chloramp

N.04.02 Vehicle

224 Comedones reduction percentage change 

(%)

Short (5) Percent change: -33 Percent change: -93

Cross-over 

Mild/mod/sev

È N=120 NS

Inter-group difference papule % change (%) Mid (10) Percent change: -52 Percent change: 65 0.01

Inter-group difference pustule % change 

(%)

Mid (10) Percent change: 51 Percent change: 90 NS

Chloramphenicol + 

hydrocortisone + sulfur

N.04.03 Chloramphenicol + sulfur

142 Severity (score)

Count location: 3 in square. 

Short (4) Measure: 26 Measure: 33

Parallel Mild/mod

N=50 NS

Total lesions change (%) Short (4) Percent change: -71 Percent change: -57 NS

Severity (score) Mid (12) Measure: 11 Measure: 8 NS

Total lesions change (%) Mid (12) Percent change: -87 Percent change: -89 NS

Chloramphenicol + 

hydrocortisone + sulfur

N.04.04 Hydrocortisone + sulfur

115 Severity change (fraser %) Short (4) Measure: -48 .001 Measure: -28

Parallel 

È N=37 .001 0.03

Severity change (fraser %) Mid (12) Measure: -64 .001 Measure: -60 .001 NS

Chloramphenicol + 

hydrocortisone + sulfur

N.04.05 Benzoyl peroxide

75 Inflammatory (count)

Baseline counts: 21 (Target) / 23 

(Comparator)

Short (4) Percent Change*: -19 NS Percent Change*: -35

Parallel Mod

È N=48 .05 NS*

Non-inflammatory (count)

Baseline counts: 40 (Target) / 37 

(Comparator)

Short (4) Percent Change*: 00 NS Percent Change*: -30 .01 NS*

Overall assessment/patient (vas) Short (4) Measure: 17 (3.) .05 Measure: 14 (4.) .05 NS*

Severity (leeds) Short (4) Measure: 2 (0.2) .01 Measure: 2 (0.3) .01 NS*

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 2 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

75 Inflammatory (count)

Baseline counts: 21 (Target) / 23 

(Comparator)

Mid (12) Percent Change*: -38 .01 Percent Change*: -37

Parallel Mod

È N=48 .01 NS*

Non-inflammatory (count)

Baseline counts: 40 (Target) / 37 

(Comparator)

Mid (12) Percent Change*: -30 NS Percent Change*: -38 .01 NS*

Overall assessment/patient (vas) Mid (12) Measure: 28 (5.) .01 Measure: 25 (8.) .01 NS*

Severity (leeds) Mid (12) Measure: 1 (0.2) .01 Measure: 2 (0.2) .01 NS*

N.05.03 Fulguration Tretinoin

31 Closed comedone change (%)

Count location: Symmetric area of face. 

Short (4) Percent change: -92 (8.) Percent change: -10 

Parallel split face (21.)

Mild

N=11 0.005

N.05.04 Fulguration Electrocautery

32 Large comedone change (%)

Count location: Symmetric area of face. 

Short (4) Percent change: -46 (23.) Percent change: -73 

Parallel split face (12.)

Mild

N=12 0.025

Small comedones change (%) Short (4) Percent change: -76 (13.) Percent change: -82 

(11.)

NS

N.07.01 Zinc Vehicle

64 Irritation (score) Short (6) Measure: 2 Measure: 1

Parallel Mild/mod

N=30 0.05

Severity (michaelsson)

Count location: Unspecified. 

Short (6) Measure: 98 Measure: 100 NS

Irritation (score) Mid (12) Measure: 1 Measure: 1 0.05

Severity (michaelsson)

Count location: Unspecified. 

Mid (12) Measure: 94 Measure: 98 NS

N.07.02 Zinc Placebo

91 Inflammatory severity (dreno)

Between P-value: inappropriate test.

Short (4) Measure: 34 (14.8) Measure: 46 (28.7)

Parallel Mod

È N=66 NS

Inflammatory severity (dreno) Mid (8) Measure: 27 (14.9) Measure: 47 (29.8) 0.02

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 3 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

N.07.02 Zinc sulfate Placebo

341 Comedones (count)

Count location: 2 cm worst. Baseline counts: 

12 (Target) / 13 (Comparator)

Short (6) Percent Change*: -50 Percent Change*: -15

Parallel Mild/mod

È N=52 NS

Cysts (count)

Count location: Face & submandibular. 

Baseline counts: 0 (Target) / 0 (Comparator)

Short (6) Percent Change*: 00 Percent Change*: -37 NS

Papules (count)

Count location: Face & submandibular. 

Baseline counts: 18 (Target) / 21 

(Comparator)

Short (6) Percent Change*: -42 Percent Change*: -19 NS

Pustules (count)

Count location: Face & submandibular. 

Baseline counts: 9 (Target) / 13 (Comparator)

Short (6) Percent Change*: -49 Percent Change*: -52 NS

Severity (michaelsson) Short (6) Measure: 21 Measure: 36 NS

211 Severity change (pillsbury %) Short (6) Measure: -33 (25.) Measure: -20 (25.)

Parallel Mild/mod/sev

N=59 0.007

341 Comedones (count)

Count location: 2 cm worst. Baseline counts: 

12 (Target) / 13 (Comparator)

Mid (12) Percent Change*: -50 Percent Change*: -38

Parallel Mild/mod

È N=52 NS

Cysts (count)

Count location: Face & submandibular. 

Baseline counts: 0 (Target) / 0 (Comparator)

Mid (12) Percent Change*: 00 Percent Change*: -33 NS

Papules (count)

Count location: Face & submandibular. 

Baseline counts: 18 (Target) / 21 

(Comparator)

Mid (12) Percent Change*: -48 Percent Change*: -37 NS

Pustules (count)

Count location: Face & submandibular. 

Baseline counts: 9 (Target) / 13 (Comparator)

Mid (12) Percent Change*: -37 Percent Change*: 02 NS

3 Severity (agrawal) Mid (12) Measure: 43 (20.8) Measure: 44 (40.8)

Parallel 

N=42 NS*

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 4 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

341 Severity (michaelsson) Mid (12) Measure: 25 (21.) Measure: 44 (32.)

Parallel Mild/mod

È N=52 NS

N.07.02 Zinc sulfate Vehicle

342 Infiltrates (count)

Baseline counts: 6 (Target) / 3 (Comparator)

Short (4) Percent Change*: 06 NS Percent Change*: 03

Parallel Mod

È N=39 NS NS

Papules (count)

Baseline counts: 28 (Target) / 41 

(Comparator)

Short (4) Percent Change*: -27 .05 Percent Change*: -34 .05 NS

Pustules (count)

Baseline counts: 10 (Target) / 7 (Comparator)

Short (4) Percent Change*: -42 .05 Percent Change*: -51 .05 NS

259 Closed comedones (count)

Baseline counts: 19 (Target) / 39 

(Comparator)

Short (6) Percent Change*: -15 NS Percent Change*: -51

Parallel Mild/mod

Í N=30 NS NS

336 Cysts (count)

Count location: Well defined regions. Baseline 

counts: 1 (Target) / 1 (Comparator)

Short (6) Percent Change*: -04 .001 Percent Change*: -02

Parallel Mod

È N=56 NS NS*

Infiltrates (count)

Count location: Well defined regions. Baseline 

counts: 2 (Target) / 1 (Comparator)

Short (6) Percent Change*: -13 .001 Percent Change*: 171 .05 NS*

259 Open comedones (count)

Baseline counts: 22 (Target) / 40 

(Comparator)

Short (6) Percent Change*: -62 NS Percent Change*: -68

Parallel Mild/mod

Í N=30 NS NS

336 Papules (count)

Count location: Well defined regions. Baseline 

counts: 29 (Target) / 19 (Comparator)

Short (6) Percent Change*: -39 NS Percent Change*: 05

Parallel Mod

È N=56 NS NS*

259 Papules (count)

Baseline counts: 14 (Target) / 16 

(Comparator)

Short (6) Percent Change*: -25 NS Percent Change*: -48

Parallel Mild/mod

Í N=30 NS NS

Pustules (count)

Baseline counts: 4 (Target) / 2 (Comparator)

Short (6) Percent Change*: -33 NS Percent Change*: 87 NS NS

336 Pustules (count)

Count location: Well defined regions. Baseline 

counts: 5 (Target) / 4 (Comparator)

Short (6) Percent Change*: -43 NS Percent Change*: -22

Parallel Mod

È N=56 NS NS*

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 5 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

259 Closed comedones (count)

Baseline counts: 19 (Target) / 39 

(Comparator)

Mid (12) Percent Change*: -34 NS Percent Change*: -45

Parallel Mild/mod

Í N=30 NS NS

342 Infiltrates (count)

Baseline counts: 6 (Target) / 3 (Comparator)

Mid (12) Percent Change*: -18 NS Percent Change*: -27

Parallel Mod

È N=39 NS NS

259 Open comedones (count)

Baseline counts: 22 (Target) / 40 

(Comparator)

Mid (12) Percent Change*: -64 NS Percent Change*: -52

Parallel Mild/mod

Í N=30 NS NS

Papules (count)

Baseline counts: 14 (Target) / 16 

(Comparator)

Mid (12) Percent Change*: -63 NS Percent Change*: -63 NS NS

342 Papules (count)

Baseline counts: 28 (Target) / 41 

(Comparator)

Mid (12) Percent Change*: -54 .01 Percent Change*: -47

Parallel Mod

È N=39 .05 NS

259 Pustules (count)

Baseline counts: 4 (Target) / 2 (Comparator)

Mid (12) Percent Change*: -62 NS Percent Change*: -25

Parallel Mild/mod

Í N=30 NS NS

342 Pustules (count)

Baseline counts: 10 (Target) / 7 (Comparator)

Mid (12) Percent Change*: -05 NS Percent Change*: -52

Parallel Mod

È N=39 .05 NS

N.07.02 Zinc sulfur Placebo

133 Comedones change (count)

Count location: Above jawline. Baseline 

counts: 39 (Target) / 41 (Comparator)

Short (6) Percent change*: -36 .001 Percent change*: -40

Parallel Mod

È N=59 .01 NS

Papules change (count)

Count location: Above jawline. Baseline 

counts: 13 (Target) / 12 (Comparator)

Short (6) Percent change*: -40 .001 Percent change*: -23 .01 NS

Pustules change (count) Short (6) Percent change*: -24 .05 Percent change*: 03 NS NS

Severity change (% michaelsson) Short (6) Measure: -33 (26.) .001 Measure: -18 (33.) .01 0.01

Severity change (michaelsson) Short (6) Measure: -19 (17.7) .001 Measure: -11 (12.3) .01 0.01

N.07.03 Zinc sulfate Oxytetracycline

232 Comedones change (count) Mid (12) Change: -25 (25.7) Change: -44 (52.6)

Parallel Mod/sev

È N=40 NS

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 6 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

232 Comedones severity change (michaelsson 

difference)

Mid (12) Measure: -14 (13.9) Measure: -24 (29.6)

Parallel Mod/sev

È N=40 NS

Overall change/patient Mid (12) Measure: 2 Measure: 2

Overall change/physician Mid (12) Measure: 2 Measure: 2

Papules change (count) Mid (12) Change: -17 (16.9) Change: -11 (14.) NS

Papules severity change (michaelsson 

difference)

Mid (12) Measure: -20 (18.7) Measure: -14 (15.2) NS

Pustules change (count) Mid (12) Change: -6 (5.6) Change: -3 (4.3) NS

Pustules severity change (michaelsson 

difference)

Mid (12) Measure: -13 (14.3) Measure: -8 (10.1) NS

Total severity change/photo (michaelsson) Mid (12) Measure: 1 Measure: 1 NS

N.07.03 Zinc sulfate/citrate complex Tetracycline

74 Nodules (count)

Baseline counts: 2 (Target) / 3 (Comparator)

Short (4) Percent Change*: -29 NS Percent Change*: 35

Parallel Mod

Í N=48 NS NS*

Non-inflammatory (count)

Baseline counts: 45 (Target) / 80 

(Comparator)

Short (4) Percent Change*: -02 NS Percent Change*: -08 NS NS*

Overall change/patient (vas) Short (4) Measure: 14 (5.) NS Measure: 10 (6.) NS NS*

Papules (count)

Baseline counts: 30 (Target) / 41 

(Comparator)

Short (4) Percent Change*: 03 NS Percent Change*: -29 NS NS*

Pustules (count)

Baseline counts: 12 (Target) / 13 

(Comparator)

Short (4) Percent Change*: -25 NS Percent Change*: -38 NS NS*

Severity (burton) Short (4) Measure: 3 (0.2) NS Measure: 3 (0.2) NS NS*

Nodules (count)

Baseline counts: 2 (Target) / 3 (Comparator)

Mid (12) Percent Change*: -13 NS Percent Change*: -50 NS NS*

Non-inflammatory (count)

Baseline counts: 45 (Target) / 80 

(Comparator)

Mid (12) Percent Change*: -11 NS Percent Change*: -40 .01 NS*

Overall change/patient (vas) Mid (12) Measure: 15 (4.) NS Measure: 28 (5.) .01 NS*

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 7 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

74 Papules (count)

Baseline counts: 30 (Target) / 41 

(Comparator)

Mid (12) Percent Change*: -13 NS Percent Change*: -49

Parallel Mod

Í N=48 .01 NS*

Pustules (count)

Baseline counts: 12 (Target) / 13 

(Comparator)

Mid (12) Percent Change*: -33 .05 Percent Change*: -46 .01 NS*

Severity (burton) Mid (12) Measure: 3 (0.1) NS Measure: 2 (0.1) .01 .001*

N.08.01 Erythromycin + zinc Vehicle

301 Comedones (count)

Count location: Face. Baseline counts: 33 

(Target) / 29 (Comparator)

Short (6) Percent Change*: -61 Percent Change*: -38

Parallel Mod

Í N=73 0.05

Inflammatory (count)

Count location: Face. Baseline counts: 20 

(Target) / 28 (Comparator)

Short (6) Percent Change*: -65 Percent Change*: -25 0.01

Severity (cook)

Count location: Face. 

Short (6) Measure: 3 .05 Measure: 5 0.05

Severity change (cook) Short (6) Measure: -2 Measure: -1

Severity (cook) Mid (10) Measure: 2 Measure: 5 0.05

Comedones (count)

Count location: Face. Baseline counts: 33 

(Target) / 29 (Comparator)

Mid (12) Percent Change*: -61 Percent Change*: -48

Inflammatory (count)

Count location: Face. Baseline counts: 20 

(Target) / 28 (Comparator)

Mid (12) Percent Change*: -73 Percent Change*: -46 0.01

Severity change (cook)

Count location: Face. 

Mid (12) Measure: -3 Measure: -1 0.001

N.08.01 Zinc + erythromycin Vehicle

321 Inflammatory change (%)

Count location: Entire face. 

Short (4) Percent change: -55 (16.) Percent change: -29 

Parallel Mild/mod (16.)

N=22 NS

Inflammatory change (%) Mid (10) Percent change: -60 (38.) Percent change: -12 

(63.)

0.05

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 8 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

N.08.02 Erythromycin + zinc Erythromycin

147 Comedones change (%) Short (4) Percent change: -35 Percent change: -25

Parallel Mod

È N=122 NS

Inflammatory change (%)

Count location: Face. 

Short (4) Percent change: -62 Percent change: -42 0.001

Severity (cook) Short (4) Measure: 3 Measure: 3 NS

Comedones change (%) Mid (12) Percent change: -62 Percent change: -40 0.001

Inflammatory change (%) Mid (12) Percent change: -85 Percent change: -48 0.001

Macules (count)

Count location: Face. Baseline counts: 9 

(Target) / 9 (Comparator)

Mid (12) Percent Change*: -36 .01 Percent Change*: 00 .02

Nodules (count)

Count location: Face. Baseline counts: 1 

(Target) / 1 (Comparator)

Mid (12) Percent Change*: -100 .01 Percent Change*: -60 NS

Severity (cook)

Count location: Face. 

Mid (12) Measure: 2 Measure: 3 0.001

N.08.02 Erythromycin + zinc acetate Erythromycin

28 Inflammatory (count)

Baseline counts: 57 (Target) / 54 

(Comparator)

Short (4) Percent Change*: -25 .001 Percent Change*: -35

Parallel Mild/mod

È N=45 .01 NS*

Non-inflammatory (count)

Baseline counts: 55 (Target) / 52 

(Comparator)

Short (4) Percent Change*: -27 .01 Percent Change*: -23 .01 NS*

Severity (leeds) Short (4) Measure: 1 (0.5) .001 Measure: 0 (0.5) .001 NS*

Inflammatory (count)

Baseline counts: 57 (Target) / 54 

(Comparator)

Mid (12) Percent Change*: -51 .001 Percent Change*: -57 .001 NS*

Non-inflammatory (count)

Baseline counts: 55 (Target) / 52 

(Comparator)

Mid (12) Percent Change*: -55 .001 Percent Change*: -44 .001 NS*

Severity (leeds) Mid (12) Measure: 0 (0.4) .001 Measure: 0 (0.5) .001 NS*

N.08.03 Erythromycin + zinc Clindamycin phosphate

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 9 of 10

ÈÍ
Trial # 

Method 

Continuous Outcome Name (Units)

Definition/Comments

Followup (wks)Comparator

Data Type: Mean (SD) Within P Data Type: Mean (SD) Within P

Target Between

 P-value

Comparison

300 Comedones change (%)

Count location: Face. 

Short (6) Percent change: -65 sig Percent change: -55

Parallel Mod

N=103 sig 0.01

Severity change (cook %) Short (6) Measure: -50 sig Measure: -30 sig 0.001

Total inflammatory change (%) Short (6) Percent change: -60 sig Percent change: -40 sig 0.05

Comedones change (%) Mid (12) Percent change: -75 sig Percent change: -65 sig NS

Severity change (cook %) Mid (12) Measure: -60 sig Measure: -50 sig NS

Total inflammatory change (%) Mid (12) Percent change: -65 sig Percent change: -55 sig 0.05

 TRIAL: - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET 

and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; 

"Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison 

between Target and Comparator arms.

EvidenceTable N CONTINUOUS: Page 10 of 10

ÈÍ